Disinfectants In Interventional Practices

Mayank Aranke, University of Texas Health Science Center at Houston
Roya Moheimani, VA Greater Los Angeles Healthcare System
Melissa Phuphanich, VA Greater Los Angeles Healthcare System
Alan D. Kaye, LSU Health Sciences Center- New Orleans
Anh L. Ngo, Harvard Medical School
Omar Viswanath, LSU Health Sciences Center- New Orleans
Jared Herman, Mount Sinai Medical Center Miami Beach


Purpose of Review: This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review’s goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures. Recent Findings: In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms. Summary: The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting.